Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN-a2b with Imatinib or Nilotinib in CP-CML
NCT00573378Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2007
- Primary completion
- Oct 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Relapse-free Survival Rate. Started Sep 2007; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00573378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573378.